Angela Lybbert, PA
Medical · Las Vegas, NVNPI 1801907621
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,479 of the $5,364 with a category attached, or 83.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 212 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$995
- Biohaven Pharmaceuticals, Inc.$841
- AstraZeneca$739
- Novo Nordisk$335
- Pfizer$281
- Amgen$245
- plus $2K from 24 others
What the payments were for
- Consulting fees$80015%
- Food & beverage$4,47984%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $995 |
| Biohaven Pharmaceuticals, Inc. | 5 | $841 |
| AstraZeneca | 24 | $739 |
| Novo Nordisk | 17 | $335 |
| Pfizer | 18 | $281 |
| Amgen | 12 | $245 |
| Bayer | 7 | $200 |
| Lilly USA, LLC | 12 | $187 |
| Astellas Pharma US Inc | 7 | $182 |
| UCB, Inc. | 9 | $168 |
| E.r. Squibb & Sons, L.L.C. | 15 | $141 |
| Si-bone, Inc. | 1 | $128 |
| Sanofi-aventis U.S. LLC | 5 | $128 |
| Novartis | 6 | $111 |
| Organon | 5 | $93 |
| Idorsia Pharmaceuticals US Inc | 4 | $80 |
| Livanova USA, Inc. | 1 | $67 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Exact Sciences | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Johnson & Johnson | 3 | $49 |
| Abbott | 2 | $43 |
| GSK | 2 | $34 |
| Boehringer Ingelheim | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Eisai Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sandoz | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- QULIPTA$135
- UBRELVY$135
- iFuse Implant$128
- BREZTRI$128
- Kerendia$122
- SAPHNELO$119
How this compares
$5,364 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $75,161 |
| TrulicityDulaglutide | 23 | $33,182 |
| RybelsusSemaglutide | 24 | $32,125 |
| EliquisApixaban | 20 | $26,920 |
| FarxigaDapagliflozin Propanediol | 16 | $25,082 |
| XareltoRivaroxaban | 19 | $19,235 |
| UbrelvyUbrogepant | 15 | $11,786 |
| Repatha SyringeEvolocumab | 11 | $6,078 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $2,144 |
| Atorvastatin Calcium | 223 | $2,020 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,604 |
| Lidocaine | 16 | $1,535 |
| Metoprolol Succinate | 76 | $1,198 |
| Valproic AcidValproic Acid (As Sodium Salt) | 13 | $1,119 |
| Levothyroxine Sodium | 97 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $335 | $107,28686 claims |
| Lilly USA, LLCTrulicity | $187 | $33,18223 claims |
| PfizerEliquis | $281 | $26,92020 claims |
| AstraZenecaFarxiga | $739 | $25,08216 claims |
| Johnson & JohnsonXarelto | $49 | $19,23519 claims |
| AbbVieUbrelvy | $995 | $11,78615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.